Clinical trial · no report yet · Phase 1

DREAMM-9

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

NCT04091126 ↗
Active, not recruiting
GlaxoSmithKline
Deep size, estimated: 301+ verified statements

We haven't built an HCP commentary report on DREAMM-9 (belantamab mafodotin plus bortezomib plus lenalidomide plus dexamethasone in newly diagnosed multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on DREAMM-9 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
26 posts on X
19 YouTube videos
3 podcast episodes

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Belantamab Mafodotin Administered in Combination With Standard of Care in Participants With Newly Diagnosed Multiple Myeloma
Phase: Phase 1
Status: Active, not recruiting
Conditions: Multiple Myeloma
Interventions: Belantamab mafodotin; Bortezomib; Lenalidomide; Dexamethasone
Arms: Cohort 1: belantamab mafodotin 1.9 mg/kg Q3/4W + VRd/Rd · Experimental
Cohort 2: belantamab mafodotin 1.4 mg/kg Q6/8W + VRd/Rd · Experimental
Cohort 3: belantamab mafodotin 1.9 mg/kg Q6/8W + VRd/Rd · Experimental
Cohort 4: belantamab mafodotin 1.0 mg/kg Q3/4W + VRd/Rd · Experimental
Cohort 5: belantamab mafodotin 1.4 mg/kg Q3/4W + VRd/Rd · Experimental
Cohort 6: belantamab mafodotin 1.4mg/kg cycle 1, 1.0 mg/kg Q9/12W Cycle 4+VRd/Rd · Experimental
Cohort 7: belantamab mafodotin 1.9 mg/kg Cycle 1, 1.4 mg/kg Q9/12W Cycle 4+VRd/Rd · Experimental
Cohort 8a : belantamab mafodotin 1.9 mg/kg Cycle 1,4; 1.4 mg/kg Q9/12W from Cycle 7 +VRd/Rd · Experimental
Cohort 8b: belantamab mafodotin 1.4 mg/kg Cycle 1,3; 1.0 mg/kg Q9/12W from Cycle 6 +VRd/Rd · Experimental
Cohort 8c: belantamab mafodotin 1.0 mg/kg Cycle 1,5;1.0 mg/kg Q9/12W from Cycle 9 +VRd/Rd · Experimental
Enrollment: 118
Primary outcomes: Number of participants with dose-limiting toxicities (DLTs)
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
Sponsor: GlaxoSmithKline
Start: Dec 18, 2019
Primary completion: Jun 2, 2025
Results posted: No
Registry record: NCT04091126 · updated Nov 28, 2025

Get this report

Deep

Report, built on orderBuilt within 24 hours of confirming your order: $1,950

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md

Indexed commentary on DREAMM-9 so far

Reports on the same drug or indication

The trial